LITTLE KNOWN FACTS ABOUT ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS.

In Section C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually ailment progression or perhaps the participants are not able to tolerate the study drugs.There may be greater treatment stress for individuals Within this trial as compared